PMID- 22385247
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20240509
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 168
IP  - 1
DP  - 2012 Apr
TI  - Sevoflurane reduces severity of acute lung injury possibly by impairing formation 
      of alveolar oedema.
PG  - 125-34
LID - 10.1111/j.1365-2249.2012.04562.x [doi]
AB  - Pulmonary oedema is a hallmark of acute lung injury (ALI), consisting of various 
      degrees of water and proteins. Physiologically, sodium enters through apical 
      sodium channels (ENaC) and is extruded basolaterally by a 
      sodium-potassium-adenosine-triphosphatase pump (Na(+) /K(+) -ATPase). Water 
      follows to maintain iso-osmolar conditions and to keep alveoli dry. We postulated 
      that the volatile anaesthetic sevoflurane would impact oedema resolution 
      positively in an in-vitro and in-vivo model of ALI. Alveolar epithelial type II 
      cells (AECII) and mixed alveolar epithelial cells (mAEC) were stimulated with 
      20 microg/ml lipopolysaccharide (LPS) and co-exposed to sevoflurane for 8 h. In-vitro 
      active sodium transport via ENaC and Na(+) /K(+) -ATPase was determined, 
      assessing (22) sodium and (86) rubidium influx, respectively. Intratracheally 
      applied LPS (150 microg) was used for the ALI in rats under sevoflurane or propofol 
      anaesthesia (8 h). Oxygenation index (PaO(2) /FiO(2) ) was calculated and lung 
      oedema assessed determining lung wet/dry ratio. In AECII LPS decreased activity 
      of ENaC and Na(+) /K(+) -ATPase by 17.4% +/- 13.3% standard deviation and 
      16.2% +/- 13.1%, respectively. These effects were reversible in the presence of 
      sevoflurane. Significant better oxygenation was observed with an increase of 
      PaO(2) /FiO(2) from 189 +/- 142 mmHg to 454 +/- 25 mmHg after 8 h in the 
      sevoflurane/LPS compared to the propofol/LPS group. The wet/dry ratio in 
      sevoflurane/LPS was reduced by 21.6% +/- 2.3% in comparison to propofol/LPS-treated 
      animals. Sevoflurane has a stimulating effect on ENaC and Na(+) /K(+) -ATPase in 
      vitro in LPS-injured AECII. In-vivo experiments, however, give strong evidence 
      that sevoflurane does not affect water reabsorption and oedema resolution, but 
      possibly oedema formation.
CI  - (c) 2012 The Authors. Clinical and Experimental Immunology (c) 2012 British Society 
      for Immunology.
FAU - Schlapfer, M
AU  - Schlapfer M
AD  - Institute of Anesthesiology, University Hospital Zurich Institute of Physiology 
      and Center for Integrative Human Physiology, University of Zurich, 
      Winterthurerstrasse 190, Zurich, Switzerland.
FAU - Leutert, A C
AU  - Leutert AC
FAU - Voigtsberger, S
AU  - Voigtsberger S
FAU - Lachmann, R A
AU  - Lachmann RA
FAU - Booy, C
AU  - Booy C
FAU - Beck-Schimmer, B
AU  - Beck-Schimmer B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Anesthetics)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Methyl Ethers)
RN  - 0 (Sodium Channels)
RN  - 0 (Sodium Isotopes)
RN  - 38LVP0K73A (Sevoflurane)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
RN  - MLT4718TJW (Rubidium)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Acute Lung Injury/drug therapy/*pathology
MH  - Anesthetics/pharmacology
MH  - Animals
MH  - Biological Transport, Active/drug effects
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Lipopolysaccharides/pharmacology
MH  - Lung/drug effects/*pathology
MH  - Male
MH  - Methyl Ethers/*pharmacology
MH  - Oxygen/analysis
MH  - Pulmonary Alveoli/drug effects/*metabolism
MH  - Pulmonary Edema/metabolism/*pathology
MH  - Rats
MH  - Rats, Wistar
MH  - Respiratory Distress Syndrome/metabolism
MH  - Rubidium/metabolism
MH  - Sevoflurane
MH  - Sodium/metabolism
MH  - Sodium Channels/drug effects
MH  - Sodium Isotopes/metabolism
MH  - Sodium-Potassium-Exchanging ATPase/metabolism
PMC - PMC3390503
EDAT- 2012/03/06 06:00
MHDA- 2012/05/05 06:00
PMCR- 2013/04/01
CRDT- 2012/03/06 06:00
PHST- 2012/03/06 06:00 [entrez]
PHST- 2012/03/06 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
PHST- 2013/04/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.2012.04562.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2012 Apr;168(1):125-34. doi: 10.1111/j.1365-2249.2012.04562.x.